Short Interest in Sanofi (NASDAQ:SNY) Drops By 17.4%

Sanofi (NASDAQ:SNY) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 3,740,000 shares, a decline of 17.4% from the November 30th total of 4,530,000 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 2,210,000 shares, the days-to-cover ratio is presently 1.7 days.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research analyst reports. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently modified their holdings of SNY. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at $29,000. Concord Wealth Partners raised its stake in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares in the last quarter. Sunbelt Securities Inc. raised its stake in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares in the last quarter. Fortitude Family Office LLC lifted its holdings in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of Sanofi during the 2nd quarter worth about $51,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Trading Up 0.6 %

Sanofi stock traded up $0.30 during midday trading on Friday, reaching $48.73. 2,221,822 shares of the stock traded hands, compared to its average volume of 2,096,043. The firm has a market cap of $123.67 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a 50-day simple moving average of $49.64 and a two-hundred day simple moving average of $52.03. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same quarter last year, the firm posted $2.55 earnings per share. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. Research analysts expect that Sanofi will post 4.06 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.